Smooth vs Textured Breast Implants: Understanding Surfaces, Shapes and Safety

The main difference in smooth vs textured breast implants is the outer shell: smooth implants have an even surface, while textured implants have a deliberately roughened surface. That distinction is separate from whether an implant is round or teardrop-shaped, and whether it contains saline or silicone gel. Surface also matters to safety discussions because breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, occurs more frequently with textured implants. However, textured devices are not all interchangeable, and having one does not automatically mean it needs to be removed.

1. What Does Smooth vs Textured Actually Mean?

Breast implant descriptions combine several characteristics. Separating them makes it easier to understand a proposed device or identify an implant you already have. Both saline-filled and silicone gel-filled breast implants have a silicone outer shell.

A silicone gel implant is therefore not necessarily textured, and a saline implant is not necessarily smooth. Likewise, knowing that an implant is round does not fully identify its surface. A useful device description includes the manufacturer, model, surface, shape and fill rather than just one familiar term.

1.1 Textured Is a Category, Not One Identical Surface

Texturing varies from relatively fine to coarse. Terms such as microtextured and macrotextured describe different surface characteristics, but a broad category alone does not establish an individual device's risk.

The UK's Medicines and Healthcare products Regulatory Agency, or MHRA, reports that BIA-ALCL cases are more often associated with macrotextured implants than microtextured or smooth implants. It also cautions that available evidence does not identify one manufacturer or model as solely responsible. These findings do not support treating every textured implant as equally risky, or calling another surface risk-free.

2. How Do Surface and Shape Affect the Comparison?

One reason for texturing is to limit unwanted implant movement or rotation. Rotation is particularly relevant to an anatomical implant because turning a teardrop-shaped device can change the breast's contour. Rotation of a round implant does not create the same orientation-related change, although displacement from its intended position remains a separate concern.

The British Association of Plastic, Reconstructive and Aesthetic Surgeons explains that anatomical implants tend to be textured for this reason. Its patient guide is helpful for understanding the design rationale, but it is not proof that a particular textured device produces better outcomes for every patient.

2.1 Potential Advantages Need Device-Specific Context

Texturing has also been used with the aim of reducing capsular contracture. A capsule is the scar tissue that forms around an implant; capsular contracture occurs when that tissue tightens around it, potentially causing firmness, pain or distortion.

Claims about preventing contracture need context, including implant placement and the specific devices being compared. A possible benefit in one surgical setting should not become a blanket claim that textured implants prevent contracture or are better overall. Ask what evidence supports the proposed model for your operation, rather than accepting a surface label as the explanation.

Similarly, smooth implants should not be described as universally more natural-looking or free of movement-related problems. The useful comparison is between realistic options for your anatomy and goals, including their limitations, not between two labels in isolation.

3. What Are the Surface-Related Safety Concerns?

3.1 BIA-ALCL Is a Lymphoma, Not Breast Cancer

BIA-ALCL is a cancer of the immune system, specifically a type of non-Hodgkin lymphoma. It usually develops in fluid or scar tissue near an implant rather than in breast tissue. It is uncommon but serious and can spread or be fatal.

The US Food and Drug Administration, or FDA, states that BIA-ALCL risk is higher with textured than smooth implants. Implant fill does not appear to be a risk factor on available evidence, but the FDA notes limitations in the research. Choosing saline rather than silicone gel should not be presented as a way to avoid this surface-related concern.

Previous devices matter too. Someone with smooth implants now may previously have had textured implants or a textured tissue expander, a temporary device used during some reconstructions. The current implant alone may not describe the person's full exposure history.

3.2 Other Reported Capsule Cancers Are Different Conditions

The FDA's safety communication issued March 8, 2023 discusses squamous cell carcinoma, or SCC, and various lymphomas other than BIA-ALCL reported in the capsule around implants. These are not all the same cancer and should not be combined into one diagnosis or one risk estimate.

Published SCC reports have involved both smooth and textured implants and both saline and silicone gel fills when device information was available. The FDA states that the cause, incidence and risk factors remain unknown. This evidence does not establish that the BIA-ALCL surface-risk pattern applies to SCC.

Reports help regulators detect safety concerns, but reported case counts alone cannot establish how likely a complication is. Missing device histories, incomplete reporting and uncertainty about the number of exposed patients limit interpretation. An absence of reports is not proof that a device has no risk.

4. Have All Textured Breast Implants Been Recalled?

No. A recall needs a specific product and country attached to it. On July 24, 2019, the FDA requested a US recall of specified Allergan BIOCELL textured implants and tissue expanders. Allergan then announced a worldwide recall of those products. The FDA's current labeling information continues to identify that recall and states that smooth-surfaced implants were not affected by it.

This was not a recall of every textured implant from every manufacturer. It also concerned removing unused affected products from distribution, not a universal instruction to remove devices already implanted.

If you have an existing implant, ask your clinician to check the exact model against the applicable regulator's current information. If surgery took place abroad, include that country in the discussion rather than assuming a US notice fully describes the device's status there.

5. What Should You Do If You Already Have Implants?

5.1 Start With Exact Device Identification

Look for your patient device card. If it is missing, request the operative report and implant records from the surgeon or facility where surgery took place. The FDA specifically recommends keeping the manufacturer and model information.

For a clinical review, try to gather:

• The manufacturer, model or style name, and serial or lot number
• The implantation date and records for each side
• Any previous implant exchanges or removals
• Details of tissue expanders used before reconstruction
• The patient labeling associated with the device

Do not try to identify surface texture by how the breast feels. Device records provide a more useful starting point. If information remains unavailable, tell the clinician what is unknown rather than assuming the implant is smooth or textured.

5.2 No Symptoms Does Not Automatically Mean Removal

The FDA does not recommend routine preventive removal of textured implants in people without symptoms solely because of BIA-ALCL concern. Its February 28, 2024 safety statement also emphasizes shared decision-making: patients should discuss possible benefits and risks of removal with their healthcare professional.

That is neither an instruction to ignore concerns nor a promise that keeping an implant carries no risk. Removal involves surgery, and the balance depends on the device, medical history, anatomy and personal priorities. An individual consultation can address those factors without assuming that everyone needs the same operation.

Possible discussions include continued follow-up, removal without replacement, or exchange where appropriate. Whether surrounding capsule tissue should also be removed is a separate clinical question. Do not assume that every removal requires the same extent of surgery or guarantees elimination of future cancer risk.

5.3 New Changes Need Assessment

Contact your surgeon or another healthcare professional promptly for persistent swelling, a new mass, pain around an implant or another new breast or implant change. BIA-ALCL symptoms can appear years after implantation. These symptoms do not diagnose cancer, and this is not an exhaustive checklist.

Assessment may involve examination, imaging and testing fluid or tissue around the implant. Evaluation before elective removal matters because a confirmed diagnosis can change the operation and specialist care needed.

6. Questions That Make a Consultation More Useful

Whether considering a new device or reviewing an existing one, ask for answers tied to the exact product:

• What are the manufacturer's name, model, surface classification, shape and fill?
• Why is this surface being proposed for my situation?
• What device-specific evidence supports its expected benefits and limitations?
• Does a recall or safety notice apply to this model in the relevant country?
• How do previous implants or expanders affect the discussion?
• What are the alternatives, including not proceeding with a new implant?
• If I keep my implants, what follow-up and symptom assessment should I arrange?
• If I consider removal or exchange, what are the surgical risks and remaining uncertainties?

For a proposed US implant, ask to review the current patient labeling and patient decision checklist. The FDA distinguishes current labeling from the original approval documents because safety information can change. Monitoring also depends on the device and clinical situation; surface terminology alone does not determine the follow-up plan.

The practical conclusion is that smooth vs textured breast implants is a comparison of one important device feature, not a complete safety verdict. Separate surface from shape and fill, identify the exact device and previous exposure history, and use an individualized clinical discussion to decide what the information means for you.